A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel

Contraception

Volumn 57, Issue 6, 1998, Pages 385-392

  Winkler, U H ^a   Howie, H ^b   Buhler K ^c   Korver, T ^d   Geurts, T B P ^e   Coelingh Bennink, H J T ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Kvinnokliniken   (Sweden)

^c Ctr Gynecol Endocrinol Repro M   (Germany)

^d Research and Development   (Netherlands)

^e Medical Services Department   (Netherlands)

Author keywords

Coagulation; Desogestrel; Fibrinolysis; Levonorgestrel; Progestogen only pills

Indexed keywords

ANTIPLASMIN; BLOOD CLOTTING FACTOR 7; CERAZETTE R; DESOGESTREL; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PLASMIN; PLASMINOGEN; PROTEIN S; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAMILY HISTORY; FEMALE; FIBRINOLYSIS; GOOD CLINICAL PRACTICE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MULTICENTER STUDY; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ADULT; CONTRACEPTIVES, ORAL, SYNTHETIC; DESOGESTREL; DOUBLE-BLIND METHOD; FACTOR VII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEMOSTASIS; HUMANS; LEVONORGESTREL; PEPTIDE FRAGMENTS; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE CONGENERS; PROTEIN S; PROTHROMBIN;

EID: 0031855374     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(98)00045-6     Document Type: Article

References (31)

1. McCann M.F., Potter L.S. Progestin-only contraception a comprehensive review . Contraception. 50:(Suppl 1):1994;S61-S62.
2. Bergink E.W., van Meel F., Turpijn E.W., van der Vies J. Binding of progestagens to receptor proteins in MCF-7 cells. J Steroid Biochem. 19:1983;1563-1570.
3. Kloosterboer H.J., Vonk-Noordergraaf C.A., Turpijn E.W. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception. 38:1988;325-332.
4. Newton J. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update. 1:1995;231-263.
5. Guillebaud J. Hormone replacement therapy (letter). Br Med J. 299:1989;50.
6. Rice C., Killick S., Hickling D., Coelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different dose levels. Hum Reprod. 11:1996;737-740.
7. Jespersen J., Bertina R.M., Haverkate F. ECAT Assay Procedures. A Manual of Laboratory Techniques. 1992;Kluwer Academic Publishers, Dordrecht.
8. Collen D., Wiman B. Turnover of antiplasmin, the fast acting plasmin inhibitor of plasma. Blood. 53:1979;313-324.
9. Fotherby K. The progestogen-only pill and thrombosis. Br J Fam Plann. 15:1989;83-85.
10. Winkler U.H., Schindler A.E., Endrikat J., Düsterberg B. A comparative study of the effects of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception. 53:1996;75-84.
11. Norris L.A., Bonnar J. The effect of oestrogen dose and progestagen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 103:1996;261-267.
12. Ball M.J., Ashwell E., Gillmer M.D.G. Progestagen-only oral contraceptives Comparison of the metabolic effects of levonorgestrel and norethisterone . Contraception. 44:1991;223-233.
13. Singh K., Viegas O.A.C., Koh C.L.S., Ratnam S.S. Effect of Norplant-2 rods on haemostatic function. Contraception. 46:1992;71-81.
14. Singh K., Viegas O.A.C., Loke D.F.M., Ratnam S.S. Evaluation of hemostatic function following Norplant implant removal. Adv Contracept. 9:1993;49-58.
15. Viegas O.A.C., Koh S.L.C., Ratnam S.S. The effects of reformulated 2-rod Norplant implant on haemostasis after three years. Contraception. 54:1996;219-228.
16. Beller F.K. Cardiovascular system Coagulation, thrombosis and contraceptive steroids - Is there a link? Goldzieher J.W., Fortherby K. Pharmacology of the Contraceptive Steroids. 1994;309-333 Raven Press, New York.
17. Lidegaard Ø. Oral contraception and the risk of cerebral thromboembolic attack results of a case-control study . Br Med J. 306:1993;956-963.
18. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO, for the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996;54:5-13.
19. Rekers H., Norpoth T., Michaels A. Oral contraceptive use and venous thromboembolism a consideration of the impact of bias and confounding factors on epidemiological studies . Eur J Contracept Reprod Health Care. 1:1996;21-30.
20. de Lignieres B. Safety of combined oral contraceptive pills. Lancet. 347:1996;548-549.
21. Bogaert M., Dhont M. Orale anticonceptiva een generatieconflict? Tijdschr Geneeskd. 52:1996;1332-1335. (in Danish).
22. van der Vies J., de Visser J. Endocrinological studies with desogestrel. Arzneimittelforschung. 33:1983;231-236.
23. Cullberg G., Dovré P.A., Lindstedt G., Steffensen K. On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand. 111:(Suppl):1982;47-54.
24. Liukko P., Erkkola R., Bergink E.W. Progestagen-dependent effect on some plasma proteins during oral contraception. Gynecol Obstet Invest. 25:1988;118-122.
25. van der Vange N., Blankenstein M.A., Kloosterboer H.J., Haspels A.A., Thijssen J.H.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, total and free testosterone. Contraception. 41:1990;345-354.
26. Winkler UH. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with (levo)norgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol (in press).
27. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briët E., Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms. Leiden Thrombophilia Study (LETS). Thromb Haemost. 71:1994;719-722.
28. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1995;1582-1588.
29. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasikalis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet. 346:1995;1589-1593.
30. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders an international case-control study . Br Med J. 312:1996;83-88.
31. Juhan-Vague I. Haemostatic parameters and vascular risk. Atherosclerosis. 124:(Suppl):1996;S49-S55.